Advertisement

Topics

Xarelto Regulatory Post-Marketing Surveillance

2015-04-09 09:50:45 | BioPortfolio

Published on BioPortfolio: 2015-04-09T09:50:45-0400

Clinical Trials [501 Associated Clinical Trials listed on BioPortfolio]

Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)

The purpose of this study is to compare the safety and efficacy of BAY59-7939 with the safety and efficacy of the licensed drug enoxaparin and a licensed oral vitamin K-antagonist and to f...

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

This is an exploratory investigation of safety, pharmacokinetic (PK) and pharmacodynamic (PD) effects of BAY59-7939 with multiple oral doses of 10 mg, 15 mg and 20 mg once daily (od) in Ja...

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

This study was a randomized, parallel group, open label trial using warfarin as comparator. Pharmacokinetics (PK) and pharmacodynamics (PD) were investigated only in BAY59-7939 groups (ori...

Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

Patients undergoing surgery, especially hip and knee surgery, are at high risk for VTE. The administration of drugs for thromboprophylaxis, such as heparins, significantly lowers that risk...

Patient and Physician Knowledge of Key Safety Messages

This cross-sectional epidemiologic study will measure physician and patient awareness and understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert card.

PubMed Articles [3956 Associated PubMed Articles listed on BioPortfolio]

Direct oral anticoagulant agents: are they so safe?

The development of direct oral anticoagulant drugs (DOACs) directed towards a specific target has represented a great innovation in terms of both pharmacological research and clinical practice. At pre...

Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.

Critically ill patients with cancer are at increased risk of venous thromboembolism (VTE) from physical and cellular factors, requiring pharmacologic prophylaxis to reduce the risk of VTE.

A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making.

Venous thromboembolism (VTE) is a major global cause of morbidity and mortality. Low molecular weight heparin (LMWH) and fondaparinux (FDP) are frequently used to treat and prevent VTE and have a vari...

Monitoring Fondaparinux in the Setting of Antithrombin Deficiency.

Heparin-induced thrombocytopenia (HIT) is a not-uncommon adverse effect of heparin exposure, with potentially serious and/or fatal thrombotic consequences. Recent studies looking at the off-label use ...

Association Between Prophylactic Low Molecular Weight Heparin Use in Pregnancy and Macrosomia: Analysis of the Ottawa and Kingston Birth Cohort.

Low molecular weight heparin (LMWH), an anticoagulant, is the recommended drug for thromboprophylaxis and treatment of venous thromboembolism (VTE) in pregnancy. During pregnancy, LMWH is routinely pr...

Medical and Biotech [MESH] Definitions

Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS.

Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.

Pharmacologic agents in the form of a mist or spray delivered into the body through the mouth.

Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.

Chemicals added to pharmacologic preparations, poisonous household goods, and other chemicals to discourage their abuse or consumption.

More From BioPortfolio on "Xarelto Regulatory Post-Marketing Surveillance"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial